Cipla Limited gets unaudited consolidated financial results for quarter ended September 30th, 2022. Differentiated pipeline unlocking and continued One-India momentum drive core revenue growth of 12 pc and expansion in EBITDA margin.
Revenue growth for the quarter was at 6 pc on a reported basis and a strong 12% on a covid adjusted base of last year; One-India Robust traction in core portfolio across therapies and business segments; 15 pc YoY ex-covid growth.
In the USA, Cipla reported a multi-quarter high of USD 179Mn in revenue and 25 pc YoY growth. The Successful launch of Lenalidomide and continued market share expansion in Lanreotide 505b2 is the main growth factor for cipla.
"Our Q2FY23 performance reflects strong momentum in One-India business and solid execution on differentiated portfolio in the US including the launch of Lenalidomide, driving our overall revenue to a multi-quarter high and expansion in our reported operating profitability, despite external headwinds. Our reported operating profitability of 22.3 pc and is tracking well within our full year guidance of 21-22 pc range. Our proactive logistics management, cost rigor and calibrated pricing actions have helped offset the adverse impact of inflationary cost elements on profits. We are closely working with USFDA on Goa observations, de-risking key assets and improving compliances holistically across manufacturing locations” Umang Vohra MD and Global CEO, Cipla Ltd.
